Profile data is unavailable for this security.
About the company
Ironwood Pharmaceuticals, Inc. is a gastrointestinal (GI) healthcare company engaged in advancing the treatment of GI diseases and redefining the standard of care for GI patients. It is engaged in the development of LINZESS (linaclotide) for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Linaclotide is also approved for the treatment of functional constipation in pediatric patients ages 6-17 years old. It is advancing apraglutide, a long-acting synthetic glucagon-like peptide-2 (GLP-2) analog being developed for rare gastrointestinal diseases, including short bowel syndrome with intestinal failure (SBS-IF) as well as several earlier stage assets. It is advancing IW-3300, a GC-C agonist, for the potential treatment of visceral pain conditions, such as interstitial cystitis/bladder pain syndrome (IC/BPS), and endometriosis. It is also developing CNP-104 for the treatment of PBC, a rare autoimmune disease targeting the liver.
- Revenue in USD (TTM)413.55m
- Net income in USD-1.05bn
- Incorporated1998
- Employees267.00
- LocationIronwood Pharmaceuticals Inc100 Summer Street, Suite 2300BOSTON 02110United StatesUSA
- Phone+1 (617) 621-7722
- Fax+1 (617) 494-0480
- Websitehttps://www.ironwoodpharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ARS Pharmaceuticals Inc | 10.00k | -49.70m | 870.12m | 24.00 | -- | 3.87 | -- | 87,011.94 | -0.5198 | -0.5198 | 0.0001 | 2.32 | 0.00004 | -- | -- | 416.67 | -19.93 | -20.37 | -20.48 | -21.32 | -- | -- | -496,960.00 | -17,491.75 | -- | -- | 0.00 | -- | -97.72 | -- | -56.75 | -- | -17.18 | -- |
| Perspective Therapeutics Inc | -304.00k | -48.91m | 880.79m | 116.00 | -- | -- | -- | -- | -0.1622 | -0.197 | -0.0009 | -- | -- | -- | -- | -2,620.69 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| USANA Health Sciences, Inc. | 900.45m | 61.94m | 889.85m | 1.80k | 14.58 | 1.78 | 11.94 | 0.9882 | 3.20 | 3.20 | 46.56 | 26.25 | 1.46 | 2.73 | -- | 500,250.00 | 10.03 | 16.23 | 12.49 | 21.75 | 80.98 | 81.42 | 6.88 | 8.96 | 3.20 | -- | 0.0026 | 0.00 | -7.77 | -4.98 | -8.02 | -12.76 | 4.86 | -- |
| Ocular Therapeutix Inc | 59.84m | -115.27m | 897.58m | 267.00 | -- | 2.20 | -- | 15.00 | -1.09 | -1.09 | 0.6335 | 2.64 | 0.1793 | 2.23 | 2.51 | 224,127.30 | -34.54 | -46.70 | -37.58 | -54.18 | 90.99 | 89.36 | -192.62 | -228.65 | 21.29 | -9.10 | 0.1401 | -- | 13.49 | 96.60 | -13.65 | -- | 26.37 | -- |
| Nurix Therapeutics Inc | 80.89m | -144.73m | 899.64m | 284.00 | -- | 4.42 | -- | 11.12 | -2.65 | -2.65 | 1.48 | 3.43 | 0.2369 | -- | -- | 284,813.40 | -42.39 | -33.01 | -54.58 | -39.66 | -- | -- | -178.93 | -260.65 | -- | -- | 0.00 | -- | 99.31 | 15.50 | 20.19 | -- | 39.42 | -- |
| Relay Therapeutics Inc | 35.33m | -329.12m | 905.30m | 309.00 | -- | 1.21 | -- | 25.63 | -2.64 | -2.64 | 0.2841 | 5.64 | 0.0376 | -- | -- | 109,371.50 | -35.03 | -28.55 | -37.16 | -29.54 | -- | -- | -931.64 | -998.20 | -- | -- | 0.00 | -- | 1,749.82 | -- | -17.72 | -- | 19.59 | -- |
| Tyra Biosciences Inc | 0.00 | -75.45m | 909.99m | 49.00 | -- | 2.33 | -- | -- | -1.68 | -1.68 | 0.00 | 7.43 | 0.00 | -- | -- | 0.00 | -22.87 | -- | -23.31 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.96 | -- | -- | -- |
| Ironwood Pharmaceuticals, Inc. | 413.55m | -1.05bn | 945.79m | 267.00 | -- | -- | -- | 2.29 | -6.79 | -6.79 | 2.52 | -2.08 | 0.5189 | -- | 4.41 | 1,548,880.00 | -135.68 | -4.54 | -164.13 | -5.20 | -- | -- | -261.50 | -7.81 | -- | 8.27 | 1.96 | -- | 7.83 | 5.02 | -672.50 | -- | 160.10 | -- |
| OPKO Health Inc | 799.60m | -252.43m | 947.91m | 3.93k | -- | 0.7567 | -- | 1.19 | -0.3427 | -0.3427 | 1.08 | 1.80 | 0.3859 | 7.53 | 6.87 | 203,461.30 | -12.18 | -7.14 | -13.58 | -8.14 | 32.63 | 34.42 | -31.56 | -13.83 | 1.58 | -4.96 | 0.2217 | -- | -14.01 | -2.70 | 42.49 | -- | -10.19 | -- |
| Liquidia Corp | 15.97m | -107.69m | 948.67m | 136.00 | -- | 10.98 | -- | 59.41 | -1.57 | -1.57 | 0.2359 | 1.13 | 0.098 | -- | 4.77 | 117,404.40 | -66.06 | -55.02 | -72.44 | -62.69 | 76.82 | 82.18 | -674.42 | -474.59 | 7.50 | -28.61 | 0.4944 | -- | 9.75 | 45.23 | -91.40 | -- | 66.93 | -- |
| Bicycle Therapeutics PLC (ADR) | 41.61m | -168.16m | 985.20m | 284.00 | -- | -- | -- | 23.68 | -4.45 | -4.45 | 1.08 | -- | 0.0853 | -- | 1.66 | 146,514.10 | -34.46 | -29.45 | -38.51 | -32.98 | -- | -- | -404.14 | -571.36 | -- | -- | 0.0796 | -- | 86.52 | 30.47 | -60.28 | -- | 19.82 | -- |
| Innoviva Inc | 311.59m | 181.39m | 985.38m | 112.00 | 7.21 | 1.41 | 4.48 | 3.16 | 2.19 | 2.19 | 3.88 | 11.21 | 0.2599 | 0.9935 | 4.10 | 2,782,054.00 | 15.13 | 26.24 | 15.57 | 28.53 | 86.12 | -- | 58.21 | 76.84 | 9.17 | -- | 0.3883 | -- | -6.30 | 3.53 | -15.99 | -14.57 | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Mar 2024 | 22.07m | 14.10% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 19.18m | 12.26% |
| Sarissa Capital Management LPas of 31 Mar 2024 | 16.39m | 10.47% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 13.92m | 8.89% |
| Pacer Advisors, Inc.as of 31 Mar 2024 | 7.21m | 4.60% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 7.10m | 4.54% |
| LSV Asset Managementas of 31 Mar 2024 | 6.15m | 3.93% |
| Armistice Capital LLCas of 31 Mar 2024 | 5.40m | 3.45% |
| Jacobs Levy Equity Management, Inc.as of 31 Mar 2024 | 4.24m | 2.71% |
| Braidwell LPas of 31 Mar 2024 | 3.49m | 2.23% |
